Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,855,808
  • Shares Outstanding, K 75,593
  • Annual Sales, $ 4,740 K
  • Annual Income, $ -66,600 K
  • 60-Month Beta 1.96
  • Price/Sales 170.42
  • Price/Cash Flow N/A
  • Price/Book 5.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.39
  • Number of Estimates 8
  • High Estimate -0.28
  • Low Estimate -0.48
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -56.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.61 +33.48%
on 01/06/20
25.83 -3.83%
on 01/17/20
+4.11 (+19.83%)
since 12/23/19
3-Month
12.59 +97.30%
on 11/06/19
25.83 -3.83%
on 01/17/20
+10.04 (+67.84%)
since 10/23/19
52-Week
12.59 +97.30%
on 11/06/19
25.83 -3.83%
on 01/17/20
+10.37 (+71.67%)
since 01/23/19

Most Recent Stories

More News
Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies

FATE : 24.84 (+1.18%)
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

The biotech sector witnesses pipeline updates from the annual ASH meet.

GILD : 63.94 (+0.80%)
AMGN : 235.04 (-0.72%)
BLUE : 89.72 (-4.35%)
FATE : 24.84 (+1.18%)
VRTX : 233.91 (-0.30%)
REGN : 356.60 (-0.71%)
SAGE : 70.46 (-1.92%)
Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model

FATE : 24.84 (+1.18%)
Fate (FATE) Announces Encouraging Data on Immunotherapies

Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

BMY : 66.87 (-0.83%)
GILD : 63.94 (+0.80%)
FATE : 24.84 (+1.18%)
BLUE : 89.72 (-4.35%)
Company News for Dec 10, 2019

Companies in the news are: ARQL, THOR, CGC, FATE

THOR : 67.99 (unch)
FATE : 24.84 (+1.18%)
ARQL : 20.00 (+0.15%)
CGC : 24.56 (+1.82%)
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019

Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat...

CNSP : 4.45 (+1.28%)
CLVS : 9.21 (+0.77%)
ARQL : 20.00 (+0.15%)
APTO : 6.23 (+0.48%)
APS.TO : 8.18 (+0.25%)
FATE : 24.84 (+1.18%)
ArQule and Fate Therapeutics soar; Sanofi and Diplomat fall

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:

BMY : 66.87 (-0.83%)
FATE : 24.84 (+1.18%)
IFF : 136.05 (+0.11%)
TCBI : 53.72 (+0.64%)
DPLO : 3.99 (unch)
Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma

FATE : 24.84 (+1.18%)
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle

FATE : 24.84 (+1.18%)
Global Acute Lymphoblastic Leukemia (ALL) Market Spotlight 2019 Featuring Fate Therapeutics, Novartis, Ono Pharmaceutical - ResearchAndMarkets.com

The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.

FATE : 24.84 (+1.18%)
NVS : 94.92 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade FATE with:

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

2nd Resistance Point 25.57
1st Resistance Point 25.20
Last Price 24.84
1st Support Level 24.33
2nd Support Level 23.83

See More

52-Week High 25.83
Last Price 24.84
Fibonacci 61.8% 20.77
Fibonacci 50% 19.21
Fibonacci 38.2% 17.65
52-Week Low 12.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar